In vivo evidence suggests that T-cell-derived gamma interferon (IFN-␥
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) establish lifelong, latent infections in the peripheral nervous system of their human hosts (3, 27, 50) . Latent HSV genomes periodically reinitiate productive phase gene expression and the de novo synthesis of infectious virus; however, the majority of these reactivation events are intercepted by the host's immune system before the secondary infection can cause disease (11, 29, 62, 63) . In experimental animals, T cells are prominent in HSV-1 latently infected ganglia and appear to be critical in the rapid suppression of HSV-1 reactivation events (5, 7, 17, 35, 51, 52) . In humans, the arrival of CD8 ϩ T cells in recurrent genital lesions correlates with clearance of HSV-2 (28, 44) . In contrast, suppression of T-cell function allows recurrent HSV infections to present as severe, disseminated lesions of the skin and mucosa (56, 57) . Although T cells are essential, the mechanism(s) by which T cells terminate HSV-1 and HSV-2 infections in vivo are not well defined.
IFN-␣, IFN-␤, and IFN-␥ are secreted proteins that play important roles in host resistance to viral infections. The 22 known isotypes of IFN-␣ share 20 to 30% amino acid homology with IFN-␤. IFN-␣ and/or IFN-␤ (IFN-␣/␤) are secreted by most cells as an innate response to viral infection, and both bind to IFN-␣/␤ receptors that are expressed on all cell types (47) . Activation of IFN-␣/␤ receptors modifies the transcriptional and translational environment in cells inducing an "antiviral state" (61) . In contrast, IFN-␥ does not share amino acid homology with IFN-␣/␤. IFN-␥ binds to a distinct receptor, and its production is restricted to activated T cells and natural killer (NK) cells (10) . While IFN-␥ is a potent immunoregulatory cytokine, IFN-␥ also directly inhibits the replication of hepatitis B virus, measles virus, and murine cytomegalovirus (CMV) in vivo (14, 42, 43, 48) .
IFN-␣/␤ are not effective inhibitors of HSV-1 replication in vitro. Although pretreatment with IFN-␣ or IFN-␤ reduces the pathogenesis of HSV-1 infections in mice and humans (21, 41) , IFN-␣ and IFN-␤ are not effective in treating established ocular herpes infections in humans (4, 26) . It has become evident that the resistance of HSV-1 to IFN-␣/␤ is an active process that is dependent on the expression of at least two viral proteins (22, 39) . The immediate-early (IE) protein ICP0 is required to prevent IFN-␣/␤ from silencing HSV-1 IE gene expression (22, 38) , and ICP34.5 is necessary to prevent the cellular double-stranded RNA-dependent protein kinase (PKR) from inhibiting protein translation in virus-infected cells (8, 31) .
IFN-␥ is an important component in the adaptive immune response to HSV-1. Administration of neutralizing antibodies to IFN-␥ increases the severity of HSV-1 infections in mice (55) . Likewise, knockout mice that lack IFN-␥ or its receptor are impaired in their capacity to control HSV-1 infection as measured by higher mortality, prolonged duration of acute HSV-1 infection, and higher frequencies of induced reactivation (5, 6, 32) . These phenotypes are consistent with a hypothesis that IFN-␥ directly inhibits HSV-1 replication in vivo but may also be explained by a general impairment of T-cell-dependent responses in IFN-␥-knockout mice.
Recombinant IFN-␥ is a weak inhibitor of HSV-1 replication in vitro (22) . Although this fact appears to be incompatible with the hypothesis that IFN-␥ inhibits HSV-1 replication in vivo, the in vitro test is not biologically relevant because T cells do not secrete IFN-␥ into environments that are devoid of other cytokines. Secretion of IFN-␣/␤, proinflammatory cytokines, and chemokines probably occurs prior to, and during, the recruitment of T cells into sites of viral infection. Therefore, a more accurate test of the in vivo situation would be to treat cell cultures with IFN-␥ and other cytokines of the innate immune response.
In testing this principle, we have found that IFN-␥ acts in concert with the innate IFNs, IFN-␣ and IFN-␤, to potently inhibit HSV-1 replication in vitro and in vivo. Treatment of Vero cells with either IFN-␤ or IFN-␥ inhibits HSV-1 replication by Ͻ20-fold. However, treatment with both IFN-␤ and IFN-␥ inhibits HSV-1 replication by ϳ1,000-fold. This inhibition is neither cell type specific, nor is it virus strain specific. Moreover, pretreatment of mouse eyes with IFN-␤ and IFN-␥ potently inhibits HSV-1 replication in vivo and prevents the development of viral pathogenesis. Because most cell types in the body secrete IFN-␣/␤ in response to viral infection (59), the results suggest that T-cell-secreted IFN-␥ may provide a second signal that suppresses HSV-1 replication in animals and thus facilitates the establishment of viral latency.
(This work was presented in part at the 2002 Experimental Biology Meeting in New Orleans and at the 27th International Herpesvirus Workshop in Cairns, Australia.)
MATERIALS AND METHODS

Cells, viruses, and IFNs. Vero and SK-N-SH cells (American Type Culture
Collection, Manassas, Va.) were propagated in Dulbecco modified Eagle medium (DMEM) containing 0.15% HCO 3 Ϫ supplemented with 10% fetal bovine serum, penicillin G (100 U/ml), and streptomycin (100 mg/ml), hereafter referred to as complete DMEM. Cultures of primary mouse kidney (PMK) cells were established from female ICR mice by standard dissociation methods and were propagated in complete DMEM.
Wild-type HSV-1 strains KOS (54), McKrae (25) , and TU1-1 were propagated in Vero cells. TU1-1 is a clinical isolate obtained at Tulane University that is two passages removed from an oral herpes lesion. TU1-1 was confirmed as HSV-1 by immunocytochemical staining of plaques with a monoclonal antibody that is specific for HSV-1 gG, whereas no staining was observed with an HSV-2 gGspecific monoclonal antibody (Rumbaugh-Goodwin Institute, Plantation, Fla.). A recombinant strain of KOS that expresses green fluorescent protein (GFP) was kindly donated by John Balliet and Priscilla Schaffer (Harvard University, Boston). This virus, KOS-GFP, was constructed by the insertion of a CMV immediate-early promoter-GFP gene cassette into the intergenic region between the UL26 and UL27 genes of HSV-1 strain KOS (John Balliet, unpublished data).
Recombinant human (hu) universal IFN-␣ (A/D), hu IFN-␤, hu IFN-␥, murine (mu) IFN-␤, and mu IFN-␥ (PBL Biomedical Laboratories, New Brunswick, N.J.) were used at concentrations of 100 U/ml, unless indicated otherwise. In all in vitro experiments, IFNs were added to cultures 12 h prior to infection, and IFN treatment was maintained continuously.
Plaque reduction and virus replication assays. For plaque reduction assays Vero cells were seeded in 12-well plates at a density of 9 ϫ 10 4 cells per well, and 6 h later 100 U/ml of IFN-␣, IFN-␤, or IFN-␥ or both IFN-␤ and IFN-␥ (100 U/ml of each) were added to the culture medium. Vero cells were inoculated with HSV-1 12 h later, and 1 h later the medium was replaced with complete DMEM containing 0.5% methylcellulose and the same IFNs used in the pretreatment. Plaques were counted 2 to 3 days later.
For viral replication assays, Vero, PMK, or SK-N-SH cells were seeded in 24-well plates at a density of 5 ϫ 10 4 cells per well, and 6 h later cultures were treated with vehicle, 100 U/ml of IFN-␤, 100 U/ml of IFN-␥, or both IFN-␤ and IFN-␥ (100 U/ml of each). Cells were inoculated 12 h later with HSV-1 at the indicated multiplicity of infection (MOI). One hour later cells were rinsed twice with 0.5 ml of complete DMEM, and the well was treated with complete DMEM containing the same IFN(s) present during the pretreatment. The cultures were freeze-thawed 24 h after infection, and the viral titer was determined on Vero cells by a 96-well microtiter plaque assay.
PCR analysis of HSV-1-infected Vero cells. Vero cells were plated in 24-well plates, and 6 h later the cells were treated with vehicle or both IFN-␤ and IFN-␥ (100 U/ml of each). Cells were inoculated 12 h later with HSV-1 strain KOS at an MOI of 0.1 to 20 PFU per cell. One hour later, cells were washed twice with 0.5 ml of complete DMEM, and DNA was isolated from each culture by a phenol-chloroform extraction procedure (60) . PCR was performed, as described below, on DNA samples to amplify a 243-bp fragment of the HSV-1 ribonucleotide reductase (RR) gene by using the oligonucleotide primers RR-a (5Ј-ATG CCAGACCTGTTTTTCAA) and RR-b (5Ј-GTCTTTGAACATGACGAAGG). The yield of 243-bp PCR product amplified from the DNA samples was quantified by densitometric analysis of ethidium bromide-stained agarose gels (Alpha Innotech Corp., San Leandro, Calif.).
Flow cytometry of KOS-GFP-infected Vero cells. Vero cells were seeded in 12-well plates at a density of 10 5 cells per well, and 6 h later cultures were treated with vehicle, 100 U/ml of IFN-␤, 100 U/ml of IFN-␥, or both IFN-␤ and IFN-␥ (100 U/ml of each). Cells were inoculated 12 h later with KOS-GFP at an MOI of 0.03. One hour later the cells were rinsed twice with 0.5 ml of complete DMEM, and the medium was replaced with complete DMEM containing the same IFN(s) present during the pretreatment. Half of the cultures were secondarily treated with 300 M acyclovir. At 1, 12, 24, and 36 h postinfection, Vero cells were treated with trypsin, resuspended in phosphate-buffered saline containing 10% fetal bovine serum, and then analyzed by using a FACSCalibur and CellQuest Pro software (Becton Dickinson Biosciences, San Jose, Calif.). At each time point, n ϭ 3 samples were analyzed per treatment group, as well as n ϭ 3 negative controls (uninfected Vero cells) and n ϭ 3 positive controls (Vero cells infected with 30 PFU/cell of a GFP-expressing adenovirus, Ad.CMV-GFP [19] ). Of the 25,000 events evaluated per sample, 24,000 Ϯ 550 (mean Ϯ the standard deviation) had forward-scatter and side-scatter properties indicating that they were single, viable cells These IFN treatments were repeated 8, 4, and 0 h before infection. At these subsequent time points, mice were anesthetized with 6.6 mg of xylazine and 50 mg of ketamine/kg (i.e., a half-dose). Mouse eyes were inoculated with 2 ϫ 10 5 PFU of HSV-1 strain KOS in a volume of 4 l. The ocular surface of both eyes was swabbed for seven consecutive days after infection with cotton-tipped applicators. The tips were placed in 0.4 ml of complete DMEM, and viral titers were determined by a microtiter plaque assay.
Measurement of HSV-1 DNA load in latently infected mouse trigeminal ganglia. DNA was isolated from the combined left and right trigeminal ganglia (TG) of mice by a phenol-chloroform extraction procedure (60) , and the number of HSV-1 genomes per TG was determined by competitive PCR as previously described (20) . A solution containing 1ϫ Taq buffer, 50 M concentrations of each deoxynucleoside triphosphates, 0.25 M concentrations of each RR primer, and 160 fg of an RR competitor template per ml (ϳ1,400 competitors per 50-l reaction) was prepared. Then, 42 l of this master mix was placed in 0.65-ml tubes and overlaid with mineral oil, and 100 ng of TG DNA (3 l) was added to each tube. The tubes were heated to 90°C in a thermal cycler, and 2.5 U of Taq polymerase diluted in 5 l of Taq buffer was added to each sample. PCR samples were incubated for 35 cycles of 94°C for 1 min 15 s, 57.7°C for 1 min 30 s, and 72°C for 40 s. Measurement of RR gene and competitor PCR product yields was performed as previously described (20, 23) .
Statistics. Analysis of numerical data and statistical analyses were performed with the software packages Microsoft Excel and Modstat (Modern Microcomputers, Mechanicsville, Va.). Data are presented as the mean Ϯ the standard error of the mean (SEM). All viral titers were transformed by adding a value of 1 such that all data could be analyzed on a logarithmic scale. Statistical comparison of viral titers (or HSV-1 genome loads) in multiple treatments was performed by one-way analysis of variance (ANOVA), followed by comparison of individual treatments to vehicle-treated controls by using Duncan's multiple range test or Tukey's post hoc t test. Regression analysis was performed by the least-squares method. Two-way ANOVA was used to compare the course of viral shedding over multiple days in mice treated with vehicle or IFNs. The polynomial trendline feature of Microsoft Excel was used to describe the sigmoidal relationship between logarithm of viral genomes per TG (x, input) and the ratio of RR to competitor PCR products (y, output) amplified from viral DNA standards (e.g., x ϭ 0.328y 3 ϩ 0.551y 2 ϩ 1.4851y ϩ 3.4423). (Table 1) . Comparable levels of inhibition could not be obtained by doubling the concentration of any one IFN from 100 to 200 U/ml (Table 1) . Likewise, simultaneous treatment of Vero cells with both IFN-␣ and IFN-␤ did not decrease HSV-1 plaque formation any more than IFN-␤ alone (Table 1) .
RESULTS
IFN-␣/␤ and IFN-␥ synergize to inhibit HSV-1 plaque formation on
If this phenomenon was receptor dependent, then one would predict that synergy would first be observed at the minimum biologically active dose of each IFN (1 U/ml, as defined by the manufacturer). Vero cells were treated with a constant, high dose of IFN-␤ and 0.5-log dilutions of IFN-␥ (Fig. 1A ). An average of 32 plaques (out of 200 PFU) formed on Vero cells treated with IFN-␤ alone. When IFN-␤ was combined with Ͻ0.3 U/ml of IFN-␥, the number of HSV-1 plaques formed on Vero cells did not change (Fig. 1A) . However, as the concentration of IFN-␥ was increased from 1 to 100 U/ml, the number of plaques that formed decreased linearly from 32 to 3 plaques per culture (Fig. 1A) . In a second experiment, Vero cells were treated with 0.5-log dilutions of IFN-␤ and a constant, high dose of IFN-␥ (Fig. 1B ). An average of 55 plaques (out of 200 PFU) formed on Vero cells treated with IFN-␥ alone. When IFN-␥ was combined with less than 0.3 U/ml of IFN-␤, the number of HSV-1 plaques formed on Vero cells did not change (Fig. 1B) . However, as the concentration of IFN-␤ was increased from 1 to 100 U/ml, the number of plaques that formed decreased linearly from 55 to 3 plaques per culture (Fig. 1B) . The results suggest that simultaneous activation of IFN-␣/␤ receptors and IFN-␥ receptors is required to synergistically inhibit HSV-1 plaque formation. IFN-␤ and IFN-␥. In vehicle-treated cultures, HSV-1 strain KOS replicated to a titer of 3.5 ϫ 10 6 PFU/ml over a 24-h period of incubation (Fig. 2) . HSV-1 replicated to titers of 3.1 ϫ 10 5 and 2.3 ϫ 10 5 PFU/ml in cultures treated with 100 U of IFN-␤ or IFN-␥/ml, respectively (Fig. 2) . Thus, treatment with IFN-␤ or IFN-␥ inhibited HSV-1 replication by Ͻ20-fold. In cultures treated with both IFN-␤ and IFN-␥, HSV-1 replicated to titers of 4.8 ϫ 10 3 PFU/ml and was inhibited by 800-fold relative to vehicle-treated cultures (Fig. 2) . Comparable levels of inhibition could not be obtained by increasing the concentration of either IFN-␤ or IFN-␥ alone to 316 or 1,000 U/ml (Fig. 2) . Whereas the level of inhibition achieved by both IFN-␤ and IFN-␥ was far greater than additive, it was considerably less than the ϳ20,000-fold inhibition achieved by the HSV DNA synthesis inhibitor, ACV (Fig. 2) .
IFN-␤ and IFN-␥ synergize to inhibit HSV-1 replication in
Treatment with IFN-␤ and IFN-␥ does not inhibit HSV-1 adsorption to Vero cells. PCR was used to compare the relative efficiency with which HSV-1 adsorbed to Vero cells treated with (i) vehicle or (ii) IFN-␤ and IFN-␥. One hour after inoculations with MOIs of 0.1 to 20 PFU/cell, DNA was isolated from HSV-1-infected Vero cells, and PCR was used to amplify a 243-bp fragment of the HSV-1 genome (Fig. 3A) . The HSV-1 RR PCR product yield increased as a function of viral MOI in Vero cells treated with vehicle ( Fig. 3B ; r 2 ϭ 0.89) or both IFN-␤ and IFN-␥ ( Fig. 3B ; r 2 ϭ 0.98). Thus, PCR provided a valid basis for comparing the relative amount of HSV-1 DNA that entered Vero cells. The considerations that account for the inherent quantitative capacity of such noncompetitive PCR assays are addressed elsewhere (15, 16) .
At all MOIs tested, the amount of RR PCR product amplified from Vero cells treated with IFN-␤ and IFN-␥ was comparable to or greater than the amount of RR PCR product amplified from vehicle-treated Vero cells (Fig. 3B) . Likewise, the correlation coefficient between MOI and PCR product yield did not differ between the treatments (P ϭ 0. (Fig. 4A) . In contrast, treatment with both IFN-␤ and IFN-␥ resulted in a gross decrease in the extent of GFP expression observed 36 h after infection (Fig. 4A) . The presence of many single GFP ϩ cells and several small foci of GFP ϩ cells suggested that IFN-␤ and IFN-␥ did not prevent KOS-GFP from entering Vero cells but rather inhibited a subsequent step in viral replication (Fig.  4A) . (Fig. 4B ). Although treatment with IFN-␤ or IFN-␥ slowed the spread of KOS-GFP, 64% Ϯ 3% of IFN-␤-treated cells and 77% Ϯ 3% of IFN-␥-treated cells were found to be GFP positive by 36 h after infection (Fig. 4B) . In contrast, only 4.0% Ϯ 0.3% of cells treated with both IFN-␤ and IFN-␥ were GFP positive 36 h after infection (Fig. 4B) .
In the presence of ACV, KOS-GFP was unable to replicate, and thus GFP expression was restricted to the ϳ3% of cells that were initially infected (Fig. 4A) . In cells treated with ACV only, flow cytometry demonstrated that GFP expression was detectable in an average of 3.1, 3.2, and 3.6% of cells by 12, 24, and 36 h after infection, respectively (Fig. 4C) . When combined with ACV, treatment with IFN-␤ slightly delayed the expression of GFP in KOS-GFP-infected cultures ( Fig. 4A and  C) . When combined with ACV, treatment with IFN-␥ had no apparent effect on GFP expression. When combined with ACV, treatment with IFN-␤ and IFN-␥ delayed GFP expression, and an average of 0.9, 1.0, and 2.2% of cells were found to be GFP positive by 12, 24, and 36 h after infection, respectively ( Fig. 4A and C) . Based on the frequency of GFP expression observed 36 h after infection, KOS-GFP entered Vero cells treated with IFN-␤ and IFN-␥ with at least 60% of the efficiency observed in vehicle-treated cells (i.e., 2.2% Ϭ 3.6%). Therefore, treatment with IFN-␤ and IFN-␥ does not prevent HSV-1 entry into Vero cells. (Table 2) . In PMK cells, the efficiency with which IFN-␤ and IFN-␥ inhibited HSV-1 replication was 24% of that achieved by ACV ( Table 2) .
The effect of IFN-␤ and IFN-␥ on the replication of HSV-1 strain KOS in Vero cells was compared to two other HSV-1 strains, McKrae and TU1-1. All three HSV-1 strains replicated to titers of greater than 2.5 ϫ 10 5 PFU/ml in vehicle-treated cells inoculated with 0.1 PFU/cell (Table 3) . Treatment with IFN-␤ or IFN-␥ reduced titers of KOS, McKrae, and TU1-1 by Յ20-fold. In contrast, treatment with both IFN-␤ and IFN-␥ reduced the titers of KOS, McKrae, and TU1-1 by 1,000-, 1,400-, and 1,800-fold, respectively ( Table 3 ). The efficiency with which IFN-␤ and IFN-␥ inhibited the replication of McKrae and TU1-1 was 25% of that achieved by ACV (Table  3) .
Pretreatment with IFN-␤ and IFN-␥ inhibits HSV-1 replication in mouse eyes. Viral replication was compared in mouse eyes that were pretreated with vehicle, IFN-␤, IFN-␥, or both IFN-␤ and IFN-␥ at 12, 8, 4, and 0 h prior to HSV-1 infection. In vehicle-treated mice, an average of 5,000 PFU/eye was detected 24 h after infection, and average titers ranged from 300 to 25,000 PFU/eye over the next 6 days (Fig. 6A) . Treatment with IFN-␤ caused an ϳ100-fold reduction in ocular HSV-1 shedding 24 h after infection, but HSV-1 titers increased to 2,700 PFU/eye by 48 h after infection (Fig. 6A) . Treatment with IFN-␥ reduced ocular HSV-1 shedding to undetectable levels 24 h after infection, and five of eight mice shed 10 to 40 PFU/eye between 2 and 7 days after infection. (Fig. 6A) . Treatment with both IFN-␤ and IFN-␥ reduced ocular HSV-1 shedding to undetectable levels 24 h after infection, and only two of eight mice shed detectable levels of virus between 2 and 7 days after infection. (Fig. 6A) . HSV-1 infection killed one of eight vehicle-treated mice and none of the IFN-treated mice. Vehicle-treated mice developed extensive periocular skin lesions by 8 days after infection (Fig. 6B) . IFN-␤-treated mice developed periocular skin lesions, but the severity of the lesions was reduced (not shown). Only two of eight IFN-␥ treated mice developed visible skin lesions. None of the eight mice treated with IFN-␤ and IFN-␥ developed periocular skin lesions by 8 days after infection, or at any other subsequent time during the 40-day course of the experiment (Fig. 6B) (Fig. 7A) . In parallel reactions, RR and competitor PCR products were coamplified from TG DNA samples isolated from HSV-1-infected mice and uninfected controls ( Fig. 7B ; competitor product yields not shown). Based on the yield of RR PCR products (normalized to the competitor), the average number of latent HSV-1 genomes in vehicletreated mice was 4.3 ϫ 10 5 viral genomes per TG (Fig. 7C) . Pretreatment of mouse eyes with IFN-␤ or IFN-␥ reduced the number of latent HSV-1 genomes per TG by 4-and 33-fold, respectively (Fig. 7C ). An average of 2.2 ϫ 10 3 viral genomes per TG were detected in mice treated with both IFN-␤ and IFN-␥ (Fig. 7C ). This latter value may be somewhat of an overestimate because the amount of amplified RR PCR product was slightly below the linear range of the competitive PCR assay (dashed line in Fig. 7C ). Therefore, pretreatment with IFN-␤ and IFN-␥ reduced the number of latent HSV-1 genomes per TG by ϳ200-fold relative to the number of HSV-1 genomes detected in TG of vehicle-treated mice.
DISCUSSION
Although HSV-1 is highly resistant to the antiviral activities of IFN-␣/␤ or IFN-␥, it is possible that the combined activities of IFN-␣/␤ and IFN-␥ could synergize to inhibit HSV-1 replication. Several reports from the 1980s contain limited evidence that is consistent with this hypothesis (9, 40, 64). Balish et al. (2) provide definitive evidence that IFN-␣ and IFN-␥ synergize to inhibit HSV-1 strain KOS replication in human corneal fibroblast cells, but the generality of the effect was not further investigated (2) . Therefore, the combined effect of IFN-␣/␤ and IFN-␥ on HSV-1 replication has never been rigorously evaluated.
The results of the present study establish that the combined activities of IFN-␣/␤ and IFN-␥ inhibit HSV-1 replication in vitro with a potency that approaches that of ACV. The results of dose-response analyses with recombinant IFN proteins indicate that (i) the effect is far greater than additive and (ii) the synergy appears to be dependent on the simultaneous activation of IFN-␣/␤ receptors and IFN-␥ receptors. Therefore, we propose that coactivation of IFN-␣/␤ and IFN-␥ receptors renders cells highly resistant to HSV-1 replication. The fact that this synergy is observed in multiple cell types and against a Vero cells were treated with vehicle, 100 U/ml of hu IFN-␤, 100 U/ml of hu IFN-␥, hu IFN-␤ and hu IFN-␥ (100 U/ml of each), or ACV (300 M). Viral titers were determined 24 h after infection with 0.1 PFU/ml of HSV-1 strains KOS, McKrae, or TU1-1.
b HSV-1 titers (log [PFU/ml]) recovered from Vero, SK-N-SH, or PMK cells (n ϭ 4 per group). The fold inhibition was calculated within each cell type as the titer in vehicle/titer in treatment.
c ‫,ء‬ P Ͻ 0.05, as determined by one-way ANOVA and Tukey's post hoc t test comparison of this treatment to vehicle-treated cultures infected with the same HSV-1 strain.
three different HSV-1 strains suggests that this is a generally applicable principal.
The results of the present study establish for the first time that the combined activities of IFN-␣/␤ and IFN-␥ potently inhibit HSV-1 replication in vivo. The potency with which IFN-␤ and IFN-␥ inhibited HSV-1 replication in vivo appeared to be considerably greater than is typically achieved when animals are treated with ACV or other antiviral agents in vivo (12, 18, 30, 36, 58) . In mice pretreated with IFN-␤ and IFN-␥, HSV-1 replication was not detected in the eyes of six of the eight mice, and the average level of virus replication in the remaining two mice was ϳ500-fold less than observed in vehicle-treated controls. Consequently, treatment with IFN-␤ and IFN-␥ prevented HSV-1-associated disease in mice and reduced the number of latent HSV-1 genomes per TG by ϳ200-fold relative to vehicle-treated mice. While IFN-␤ reduced the severity of disease, HSV-1 still replicated to high titers in mice treated with IFN-␤ alone. Treatment with IFN-␥ alone, however, inhibited HSV-1 replication with nearly the same potency as that of IFN-␤ and IFN-␥ together. We hypothesize that the high level of inhibition achieved by exogenous IFN-␥ alone is the result of synergy with endogenous IFN-␣/␤ that is locally produced in response to HSV-1 infection. The validity of this hypothesis remains to be tested. amplified from viral DNA standards. These DNA standards consisted of (i) twofold dilutions of HSV-1 genomes, (ii) a constant amount of competitor (ϳ1,400 copies), and (iii) 100 ng of uninfected TG DNA. Duplicate blots of PCR products were hybridized to RR-specific or competitor-specific probes, and the ratio of RR to competitor PCR product was used to define the "normalized RR PCR product yield." The relationship between the number of viral genomes per TG (x, input) and the normalized RR PCR product yield (y, output) was sigmoidal and was described by the polynomial equation: x ϭ 0. and IFN-␥ was highly dependent on the multiplicity of HSV-1 infection (r 2 ϭ 0.99). Thus, we hypothesize that IFN-␤ and IFN-␥ synergize to inhibit the expression of at least one virusencoded function that is necessary for HSV-1 replication. For example, if IFN-␣/␤ and IFN-␥ synergistically block the expression of ICP0 or ICP34.5, HSV-1 would be highly sensitive to inhibition by IFN-␣/␤ (22, 39) . If this hypothesis is correct, then increasing the copy number of either ICP0 and/or the ICP34.5 genes should be sufficient to overcome inhibition by IFN-␣/␤ and IFN-␥. Investigations are currently in progress to test these and other hypotheses regarding the mechanism(s) by which IFN-␣/␤ and IFN-␥ synergistically block HSV-1 replication.
Implications. (i) Host immunity to HSV-1. Three pieces of evidence are consistent with a hypothesis that T cells inhibit HSV-1 replication in the peripheral nervous system through noncytolytic mechanisms. First, despite their best known role as cytotoxic T lymphocytes, CD8
ϩ T cells actually contribute to the survival of HSV-1 infected neurons in mice (53) . Second, during acute HSV-1 infection, ganglionic neurons surrounded by CD8
ϩ T cells remain healthy in appearance (35) . Finally, CD8
ϩ T cells are sufficient to block HSV-1 reactivation from TG neurons ex vivo, and this activity can be blocked with neutralizing antibodies to IFN-␥ (33, 34) .
The results of the present study are consistent with a hypothesis that secretion of IFN-␥ suppresses HSV-1 replication in vivo. If IFN-␣ and/or IFN-␤ are produced as an innate response to viral infection (61), then it follows that IFN-␣/␤ are ubiquitous in virus-infected tissues. Extrapolating from the in vitro results, one can imagine that the ϳ10-fold inhibition achieved by IFN-␣/␤ would reduce the rate of HSV-1 replication but would not stop the spread of virus in vivo. Secretion of IFN-␥ from T cells and/or NK cells, however, may provide a second signal that synergizes with IFN-␣/␤ and renders cells far less permissive to HSV-1 replication. Thus, the ϳ1,000-fold inhibition achieved by the combined activities of IFN-␣/␤ and IFN-␥ may effectively stop HSV-1 infection from spreading in vivo.
Under this hypothesis, cells that are capable of secreting IFN-␥ should be essential components of the host immune response to HSV-1. Depletion of either CD4 ϩ , CD8 ϩ , or ␥␦ ϩ T-cell subsets grossly impairs the host immune response to HSV-1 (37, 49, 53) . Likewise, depletion of NK cells significantly increases the pathogenesis of HSV-1 infections (1, 45) . Therefore, the primary cell types that are capable of secreting IFN-␥ in vivo are all important for host immunity to HSV-1.
(ii) Establishment of latent infections. The fact that IFN-␤ and IFN-␥ synergize to inhibit the replication of HSV-1 has important implications for the coevolution of herpesviruses and their vertebrate hosts. Most viral infections have two possible outcomes: (i) the virus kills the host or (ii) the host clears the virus. In vertebrate animals, it is the clonal proliferation and dissemination of virus-specific T cells that allows the host to clear the virus. The results of the present study raise the intriguing possibility that HSV, and perhaps other herpesviruses, have evolved to respond to T-cell-secreted cytokines as cues that trigger the efficient suppression of viral replication at appropriate times. By coupling repression of virus replication to the infiltration of T cells into infected tissues, a third possible outcome of viral infection may be created: the establishment of latent infections that persist in an equilibrium with the host's immune system. In light of this hypothesis, it is intriguing that secretion of IFN-␥ from T cells also inhibits the replication of hepatitis B virus, an unrelated persistent virus (13, 14, 46) .
(iii) Clinical relevance. Although IFNs are not considered clinically effective in treating HSV-1 infections, only IFN-␣ and IFN-␤ have been tested in humans (24) . In the present study, IFN-␥ was a far more potent inhibitor of HSV-1 replication in vivo than IFN-␤. Recombinant IFN-␥ has never been clinically evaluated for its potential in treating human HSV-1 infections, nor has recombinant IFN-␥ been rigorously evaluated in animal models of HSV-1 infection.
If IFN-␣/␤ are ubiquitous in HSV-infected tissues, then treatment with IFN-␣ or IFN-␤ can only increase the levels of a preexisting cytokine. However, if secretion of IFN-␥ from T cells is truly rate limiting (particularly in the immunodeficient), then there is a clear theoretical rationale for determining if exogenous IFN-␥ can be used to limit the spread of HSV-1 infection in vivo. Further investigation will be required to determine whether IFN-␥ has any potential application in limiting the replication and pathogenesis of HSV-1 in humans.
